S
SeLux Diagnostics
SeLux Diagnostics is developing universal synthetic amplifier technology equipment for antibiotic susceptibility testing and diagnostics
About SeLux Diagnostics
Selux Diagnostics is a healthcare startup that operates in the field of antibiotic susceptibility testing (AST). The company's mission is to combat antimicrobial resistance (AMR), a global health crisis that is seeing bacteria evolve faster than science, leading to resistance to lifesaving antibiotics. Selux aims to preserve the effectiveness of antibiotics for future generations by providing faster diagnostic results, comprehensive susceptibility testing, and updated breakpoints.
The company's primary clients are hospitals and healthcare providers who need accurate and rapid AST to prescribe the correct antibiotics. Selux's technology allows testing against all commercially relevant antibiotics at once, which is a significant innovation in a field that hasn't seen substantial progress in over two decades.
Selux's business model revolves around providing its AST technology to healthcare providers. The company makes money by selling its testing services, which are crucial in the fight against antibiotic resistance. By providing faster and more accurate results, Selux helps reduce the unnecessary or incorrect prescription of antibiotics, which is a significant issue in hospitals.
In summary, Selux Diagnostics is a pioneering healthcare startup that is addressing the global health crisis of antibiotic resistance through its innovative AST technology. The company serves healthcare providers by offering rapid and comprehensive antibiotic susceptibility testing, helping to ensure the correct prescription of antibiotics and ultimately saving lives.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Boston, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 59.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Health Diagnostics, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2024 | $48M | $192M | Schooner Capital · Northpond Ventures · RA Capital Management | ↗ |
| DEBTDebt | Feb 2024 | $40M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for SeLux Diagnostics is 2.3K monthly website visits, down 28.1% over the last three months. SeLux Diagnostics's team declined 26.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
US Biomedical Advanced Research and Development Authority
Series A3 investors entered at this stage
Sands Capital Management- SCSchooner Capital
RA Capital Management
Series B and later2 investors entered at this stage
Northpond Ventures
Oxford Finance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SeLux Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SeLux Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





